All In Biotech

NDA 212020 · Exela Pharma

Tranexamic Acid

Tranexamic Acid · Intravenous · Antifibrinolytic Agent

Last checked: Nov 20, 2026Latest source record: Jul 16, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Apr 15, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

728

175 Phase 3, 72 recruiting

FAERS reports

8,564

7,951 serious, 1,245 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 22, 2019.

Tranexamic Acid in Sodium Chloride Injection is indicated in patients with hemophilia for short-term use (two to eight days) to reduce the risk of hemorrhage during and following tooth extraction. Tranexamic Acid in Sodium Chloride Injection is an antifibrinolytic indicated in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction ( 1 ).

Mechanism: Tranexamic acid is a synthetic lysine amino acid derivative, which diminishes the dissolution of hemostatic fibrin by plasmin. In the presence of tranexamic acid, the lysine receptor binding sites of plasmin for fibrin are occupied, preventing binding to fibrin monomers, thus preserving and stabilizing fibrin’s matrix structure. The antifibrinolytic effects of tranexamic acid are mediated by reversible interactions at multiple binding sites within plasminogen. Native human plasminogen contains 4 to 5 lysine binding sites with low affinity for tranexamic acid (Kd = 750 μmol/l) and 1 with high...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 15, 2019 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • TRANEXAMIC ACID · TRANEXAMIC ACID 1GM/100ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Tranexamic Acid" as an intervention, any sponsor and status, largest first.

All 728 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective641
  • off label use632
  • pyrexia347
  • hypotension322
  • nausea322
  • diarrhoea308
  • haemorrhage296
  • vomiting290
  • dyspnoea283
  • pneumonia265
  • febrile neutropenia246
  • anaphylactic reaction230

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200437
200533
200639
200731
200865
200962
2010144
2011181
2012164
2013161
2014173
2015263
2016296
2017385
2018445
2019632
2020579
2021806
2022843
2023675
2024917
2025997
2026636

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tranexamic Acid* (Tranexamic Acid)

2024 spending

$3.0M

Beneficiaries

44,332

61,627 claims

Per beneficiary

$67

$1.68 per unit

View as table
YearSpending
2020$2,050,716
2021$2,255,375
2022$2,618,450
2023$2,914,037
2024$2,982,036

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,180 on PubMed

Sponsor: Exela Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.